Novartis AG
DOSING OF A BISPECIFIC ANTIBODY THAT BIND CD123 AND CD3
Last updated:
Abstract:
The methods described here are directed to treating human subjects with bispecific anti-CD 123.times.anti-CD3 antibodies.
Status:
Application
Type:
Utility
Filling date:
3 Jun 2019
Issue date:
8 Jul 2021